{
"id":"mk19_a_id_t13",
"number":13,
"bookId":"id",
"title":{
"__html":"Clinical Manifestations, Diagnostic Testing, and Treatment of Lyme Disease by Stage of Infection "
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7b4817",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 13. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t13"
}
]
},
"Clinical Manifestations, Diagnostic Testing, and Treatment of Lyme Disease by Stage of Infection "
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64973d",
"class":"col hd l",
"children":[
"Lyme Stage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56b87e",
"class":"col hd l",
"children":[
"Onset after Infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"191026",
"class":"col hd l",
"children":[
"Clinical Findings"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48de1f",
"class":"col hd l",
"children":[
"Laboratory Confirmation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ac19d",
"class":"col hd l",
"children":[
"Treatment",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62797a",
"class":"cell txt l",
"children":[
"Early localized"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f16527",
"class":"cell txt l",
"children":[
"≤4 wk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5799c0",
"class":"cell txt l",
"children":[
"EM at site of tick attachment, variably with fever, lymphadenopathy, myalgia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9f4f1",
"class":"cell txt l",
"children":[
"Not needed if EM present"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f64844",
"class":"cell txt l",
"children":[
"Doxycycline, 100 mg PO BID × 10 d (first-line therapy)"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"a44333",
"class":"cell txt l",
"children":[
"Amoxicillin, 500 mg PO TID × 14 d"
]
},
" ",
{
"type":"p",
"hlId":"8e0c4e",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"259491",
"class":"cell txt l",
"children":[
"Cefuroxime axetil, 500 mg PO BID × 14 d"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af9e3e",
"class":"cell txt l",
"children":[
"Early disseminated"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"600770",
"class":"cell txt l",
"children":[
"2 wk-6 mo"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db774",
"class":"cell txt l",
"children":[
"Constitutional: Multiple sites of EM, flu-like syndrome"
]
},
" ",
{
"type":"p",
"hlId":"c14390",
"class":"cell txt l",
"children":[
"Cardiac: heart block, myocarditis"
]
},
" ",
{
"type":"p",
"hlId":"035c7b",
"class":"cell txt l",
"children":[
"Neurologic: cranial neuropathies, meningitis, radiculitis, mononeuritis multiplex, spinal cord or brain parenchymal inflammation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"affa77",
"class":"cell txt l",
"children":[
"Not needed if EM is present; otherwise, two-tier serologic testing"
]
},
" ",
{
"type":"p",
"hlId":"75cd2a",
"class":"cell txt l",
"children":[
"CSF evaluation when CNS involvement is a concern"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f30294",
"class":"cell txt l",
"children":[
"1. Cardiac"
]
},
" ",
{
"type":"p",
"hlId":"1b8155",
"class":"cell txt l",
"children":[
"Hospitalized patients (first-degree block with PR interval ≥300 msec, higher degree heart block, other arrhythmias, myopericarditis): initial IV ceftriaxone with transition to oral for total of 14-21 days"
]
},
" ",
{
"type":"p",
"hlId":"0aae2e",
"class":"cell txt l",
"children":[
"Outpatients (first-degree AV block with PR interval <300 msec): oral treatment same as for early localized disease × 14-21 d"
]
},
" ",
{
"type":"p",
"hlId":"d0d2cd",
"class":"cell txt l",
"children":[
"2. Meningoencephalitis: IV penicillin G, IV cefotaxime, or IV ceftriaxone or oral doxycycline × 14-21 d (IV antibiotics preferred for spinal or brain parenchymal involvement)"
]
},
" ",
{
"type":"p",
"hlId":"1b1fd2",
"class":"cell txt l",
"children":[
"3. Other manifestations (including facial palsy): oral treatment the same as for early localized disease × 14-21 d"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3fbafb",
"class":"cell txt l",
"children":[
"Late disseminated"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b3294",
"class":"cell txt l",
"children":[
"≥6 mo"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5726cb",
"class":"cell txt l",
"children":[
"Arthritis; neurologic symptoms (peripheral neuropathy, encephalopathy), or dermatologic symptoms (acrodermatitis chronica atrophicans)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8db96f",
"class":"cell txt l",
"children":[
"Two-tier serologic testing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57c745",
"class":"cell txt l",
"children":[
"Initial rheumatologic treatment: same as for early localized but × 28 d"
]
},
" ",
{
"type":"p",
"hlId":"cfdcaf",
"class":"cell txt l",
"children":[
"Arthritis unresponsive to initial treatment: IV ceftriaxone 2-4 weeks"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"AV = atrioventricular; BID = twice daily; CSF = cerebrospinal fluid; CNS = central nervous system; EM = erythema migrans; IV = intravenous; PO = by mouth; TID = three times daily."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Doses are for adults with normal kidney function."
]
]
}